ArticlePharmaceuticals (Basel, Switzerland)2019
De Novo Design and In Vitro Testing of Antimicrobial Peptides against Gram-Negative Bacteria.
Article in Pharmaceuticals (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Cooperative membrane association as a mechanistic origin of synergistic antimicrobial peptide activity.RSC chemical biology · 2026Review
- Antimicrobial effects of novel Hermetia illucens peptides.Scientific reports · 2026Article
- Antimicrobial peptides in the era of resistance: integrating AI-driven design, host-microbe interactions, and nanotechnological delivery.Frontiers in microbiology · 2026Review
- The antimicrobial peptide EM86 loaded to gamma-irradiated sodium alginate/polyvinyl alcohol electrospun nanofibrous dressing treated multidrug-resistantFrontiers in bioengineering and biotechnology · 2026Article
- Identification and Characterization of Glycine- and Proline-Rich Antioxidant Peptides From Antler Residues Based on Peptidomics, Machine Learning, and Molecular Docking.Food science & nutrition · 2025Article
- Salt-Tolerant, Protease-Stable and Non-Resistance Developing Cationic AMPs for Combatting Planktonic MRSA and its Biofilms.ACS medicinal chemistry letters · 2025Article
- Can large language models predict antimicrobial peptide activity and toxicity?RSC medicinal chemistry · 2024Article
- Article
- Novel antimicrobial peptides against Cutibacterium acnes designed by deep learning.Scientific reports · 2024Article
- Efficacy of Ceragenins in Controlling the Growth of Oral Microorganisms: Implications for Oral Hygiene Management.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Impact of C- and N-terminal protection on the stability, metal chelation and antimicrobial properties of calcitermin.Scientific reports · 2023Article
- Novel cationic cryptides in Penaeus vannamei demonstrate antimicrobial and anti-cancer activities.Scientific reports · 2023Article
- Diversity of Antimicrobial Peptides in Silkworm.Life (Basel, Switzerland) · 2023Review
- A Novel Peptide with Antifungal Activity from Red Swamp CrayfishAntibiotics (Basel, Switzerland) · 2022Article
- Modulation of free energy landscapes as a strategy for the design of antimicrobial peptides.Journal of biological physics · 2022Article
- Article
- Design of Membrane Active Peptides Considering Multi-Objective Optimization for Biomedical Application.Membranes · 2022Review
- dbAMP 2.0: updated resource for antimicrobial peptides with an enhanced scanning method for genomic and proteomic data.Nucleic acids research · 2022Article
- How to Combat Gram-Negative Bacteria Using Antimicrobial Peptides: A Challenge or an Unattainable Goal?Antibiotics (Basel, Switzerland) · 2021Review
- Accelerating antibiotic discovery through artificial intelligence.Communications biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Antimicrobial peptides (AMPs) have been identified as a potentially new class of antibiotics to combat bacterial resistance to conventional drugs. The design of de novo AMPs with high therapeutic indexes, low cost of synthesis, high resistance to proteases and high bioavailability remains a challenge. Such design requires computational modeling of antimicrobial properties. Currently, most computational methods cannot accurately calculate antimicrobial potency against particular strains of bacterial pathogens. We developed a tool for AMP prediction (Special Prediction (SP) tool) and made it available on our Web site (https://dbaasp.org/prediction). Based on this tool, a simple algorithm for the design of de novo AMPs (DSP) was created. We used DSP to design short peptides with high therapeutic indexes against gram-negative bacteria. The predicted peptides have been synthesized and tested in vitro against a panel of gram-negative bacteria, including drug resistant ones. Predicted activity against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.